Trelegy

Alternative Names: Umeclidinium/Vilanterol/Fluticasone furoate

Umeclidinium/Vilanterol/Fluticasone furoate (brand name Trelegy Ellipta) is a once-daily inhaled triple therapy approved for the maintenance treatment of COPD. It combines a LAMA (umeclidinium), LABA (vilanterol), and ICS (fluticasone furoate) to improve lung function, reduce symptoms, and prevent exacerbations. This combination targets airway constriction, inflammation, and mucus production—key components of COPD. Trelegy is typically used in patients who continue to have symptoms or frequent flare-ups despite using single or dual inhaler therapies. Common side effects include headache, sore throat, and increased risk of respiratory infections.

Treatment Type: Prescription Medication

Treatment Class: Beta Agonist

Treatment Modality: Inhalation

Trelegy

Review Summary

4.0

1 Reviews

Preferred by 1 Reviewers

Based on the review, Umeclidinium/Vilanterol/Fluticasone furoate (Trelegy Ellipta) is considered a convenient and effective once-daily triple therapy for COPD patients with ongoing symptoms or frequent exacerbations. The treatment combines three different types of medications in a single inhaler, which is beneficial, though its non-generic status may impact affordability.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
2.0
1 = Very Expensive 5 = Very Affordable

2.0

Expensive
Relief Speed
4.0
1 = No Relief 5 = Immediate Relief

4.0

Fast Relief
Side Effects
4.0
1 = Intolerable Effect 5 = No Effect

4.0

Mild Effect
Treatment Line
3.0
1 = Third-line or more 5 = First-line

3.0

Second Line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.0

1 Reviews
5
0%
4
100%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the review, Umeclidinium/Vilanterol/Fluticasone furoate (Trelegy Ellipta) is considered a convenient and effective once-daily triple therapy for COPD patients with ongoing symptoms or frequent exacerbations. The treatment combines three different types of medications in a single inhaler, which is beneficial, though its non-generic status may impact affordability.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
2 months ago
Trelegy is a convenient inhaler that combines three medications in one device: an inhaled corticosteroid, a long-acting beta agonist, and a long-acting muscarinic antagonist. This triple therapy can be very effective for patients with COPD or more severe asthma who need multiple mechanisms of treatment. The main advantage is simplicity—one inhaler once daily instead of juggling several medications. The downside is potentially cost, as Trelegy can be expensive, and similar treatment combinations can often be achieved using two separate inhalers at a lower price.
#Expensive #CoveredByInsurance #FastRelief #MildEffect #Second-line #Maintenance
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All